Predictive oncology reports year-end 2024 financial results and provides corporate update

Pittsburgh, april 01, 2025 (globe newswire) -- predictive oncology (nasdaq: poai), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and clia laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended december 31, 2024, and provided a corporate update. the company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended december 31, 2024.
POAI Ratings Summary
POAI Quant Ranking